Aimei Health Technology Co., Ltd (AFJK) P/E Ratio History
ExpensiveTrading at 157.0x vs 5Y avg 107.3x · 86th percentile · Material premium to history · Data 2024–2026
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, Aimei Health Technology Co., Ltd (AFJK) trades at a price-to-earnings ratio of 157.0x, with a stock price of $26.69 and trailing twelve-month earnings per share of $0.88.
The current P/E is 46% above its 5-year average of 107.3x. Over the past five years, AFJK's P/E has ranged from a low of 37.8x to a high of 368.5x, placing the current valuation at the 86th percentile of its historical range.
Compared to the Financial Services sector median P/E of 14.3x, AFJK trades at a 999% premium to its sector peers. The sector includes 800 companies with P/E ratios ranging from 0.0x to 157.0x.
Relative to the broader market, AFJK commands a significant premium over the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AFJK DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
AFJK Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
AFJK P/E vs Peers
Healthcare and life sciences SPACs peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $6B | 69.1 | 1.95 | -10% | |
| $1B | 35.5 | - | +104%Best | |
| $8B | 70.9 | - | -4% | |
| $4B | 23.2Lowest | 0.44Best | -12% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
AFJK Historical P/E Data (2024–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $24.50 | $0.17 | 146.2x | +36% |
| FY2025 Q4 | Dec 31 2025 | $64.01 | $0.17 | 368.5x | +243% |
| FY2025 Q3 | - | $11.32 | $0.20 | 56.9x | -47% |
| FY2025 Q2 | Jun 30 2025 | $11.15 | $0.22 | 50.3x | -53% |
| FY2025 Q1 | Mar 31 2025 | $11.00 | $0.22 | 50.1x | -53% |
| FY2024 Q4 | - | $10.70 | $0.28 | 37.8x | -65% |
| FY2024 Q3 | Sep 30 2024 | $10.48 | $0.25 | 41.4x | -61% |
Average P/E for displayed period: 107.3x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AFJK — Frequently Asked Questions
Quick answers to the most common questions about buying AFJK stock.
What is AFJK's P/E ratio?
Aimei Health Technology Co., Ltd (AFJK) trailing twelve-month P/E ratio is 157.0x, based on TTM diluted EPS of $0.88. The 5-year average P/E is 107.3x and the historical range spans 37.8x to 368.5x.
Is AFJK stock overvalued or undervalued?
AFJK trades at 157.0x P/E, above its 5-year average of 107.3x. The 86th percentile ranking within the 37.8x–368.5x historical range indicates a premium to historical valuation.
Is AFJK stock expensive?
Yes, AFJK is expensive relative to its own history. The current P/E of 157.0x is above the 5-year average of 107.3x and also above the Financial Services sector median of 14.3x. The stock sits at the 86th percentile of its 5-year valuation range.
What is AFJK's historical P/E range?
Over the past 5 years, AFJK's P/E ratio has ranged from 37.8x to 368.5x, with a median of 50.3x and an average of 107.3x. The current P/E of 157.0x places the stock at the 86th percentile of this range. Full historical data spans 2024–2026.
How does AFJK's P/E compare to the S&P 500?
AFJK trades at 157.0x P/E versus the S&P 500 median of 25.9x. The 506% premium to the market typically reflects higher expected earnings growth or quality.
How does AFJK's valuation compare to Financial Services peers?
Aimei Health Technology Co., Ltd P/E of 157.0x compares to the Financial Services sector median of 14.3x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is AFJK's PEG ratio?
AFJK PEG ratio is N/A, based on a P/E of 157.0x and EPS growth of -39.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is AFJK's earnings yield?
AFJK earnings yield is 0.64%, the inverse of its 157.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.